Usana Health Sciences INC 8-K filings

USANA Health Sciences announced a second-quarter net loss of $21.4 million and reduced its fiscal year 2026 guidance, citing underperformance in its ventures businesses.

USANA Health Sciences held its Annual Meeting of Shareholders on May 20, 2026, with strong participation and key votes on board directors, auditor ratification, and executive compensation.

USANA Health Sciences announced its first quarter 2026 financial results, showing flat net sales and a decrease in net earnings, while reiterating its full-year guidance.

USANA Health Sciences, Inc. has disclosed the compensation packages for its reappointed CEO, Kevin Guest, and the transition agreement for former CEO Jim Brown.

USANA Health Sciences announced preliminary fiscal year 2025 net sales of $925 million, surpassing its guidance, and issued an initial fiscal year 2026 net sales outlook of $925 million to $1.0 billion, driven by growth in Hiya and Rise Wellness despite a projected decline in its core nutritional business.

USANA Health Sciences announced a leadership transition with Kevin Guest returning as Chief Executive Officer, succeeding Jim Brown, to accelerate growth and enhance shareholder value.

USANA Health Sciences announced a net loss of $6.5 million for Q3 2025 and significantly lowered its full-year financial guidance, citing softer sales and higher tax rates.

USANA Health Sciences announced preliminary third quarter 2025 results, revealing a significant drop in profitability and a net loss, despite a modest increase in net sales.

USANA Health Sciences announced its second quarter 2025 financial results, reporting 11% year-over-year net sales growth but a decline in net earnings and active direct selling customers, while reiterating its full-year fiscal 2025 outlook.

USANA Health Sciences, Inc. has entered into a Third Amended and Restated Credit Agreement providing a $75 million revolving credit facility, with an option to increase by an additional $200 million, maturing in June 2030.

USANA Health Sciences introduces the 2025 Equity Incentive Plan to align employee and director interests with shareholder value, replacing the 2015 plan.

USANA Health Sciences announced its Q1 2025 financial results, showing revenue growth but a decrease in net earnings, while reiterating its full-year outlook.

USANA Health Sciences finalizes acquisition of a controlling stake in Hiya Health Products, LLC, a children's wellness e-commerce company, through a merger agreement.

USANA Health Sciences reports a decrease in net sales and earnings for Q4 and fiscal year 2024, but anticipates growth in 2025 following the acquisition of Hiya Health Products.

USANA Health Sciences has acquired a 78.8% controlling interest in Hiya Health Products, a direct-to-consumer children's health and wellness company, for $205 million in cash.

USANA Health Sciences announced a decrease in third-quarter sales and earnings per share, while also revising its full-year outlook due to continued macroeconomic headwinds.

USANA Health Sciences reported a decline in second-quarter sales and earnings, leading to a reduced full-year outlook due to macroeconomic pressures and unfavorable currency exchange rates.

USANA Health Sciences held its annual shareholder meeting on May 6, 2024, where directors were elected, the auditor was ratified, and executive compensation was approved on an advisory basis.

USANA Health Sciences reported a decrease in first-quarter net sales and diluted EPS compared to the previous year, but saw growth in China which helped offset declines in other regions.

USANA Health Sciences reported a decrease in year-over-year sales and earnings for 2023, but exceeded expectations in Q4, and provided a cautious outlook for 2024.